EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

John M Kirkwood, Peter Mohr, Christoph Hoeller, Jean-Jacques Grob, Michele Del Vecchio, Jennifer Lord-Bessen, Swetha Srinivasan, Ayman Nassar, Federico Campigotto, Hannah Fairbanks, Fiona Taylor, Rachael Lawrance und 2 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115371 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von John M Kirkwood und 13 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: kirkwoodjm@upmc.edu. Hauptthemen laut MEDLINE: Nivolumab, Melanoma, Patient Reported Outcome Measures, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabMelanomaPatient Reported Outcome MeasuresSkin NeoplasmsAntineoplastic Agents, ImmunologicalHumansQuality of LifeMaleFemaleChemotherapy, AdjuvantMiddle AgedAgedNeoplasm StagingAdultDouble-Blind Method

Stichwörter der Autor:innen

Adjuvant therapyHealth-related quality of lifeNivolumabStage IIB/C melanoma

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: kirkwoodjm@upmc.edu.
  • Elbe-Kliniken Buxtehude, Buxtehude, Germany.
  • Medical University of Vienna, Vienna, Austria.
  • Aix-Marseille University, Hôpital de la Timone, Marseille, France.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Bristol Myers Squibb, Princeton, NJ, USA.

Förderung

  • Bristol-Myers Squibb Company

Zitieren

APA

Kirkwood, J. M., Mohr, P., Hoeller, C., Grob, J. J., Del Vecchio, M., Lord-Bessen, J., Srinivasan, S., Nassar, A., Campigotto, F., Fairbanks, H., Taylor, F., Lawrance, R., Long, G. V., & Weber, J. (2025). Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115371

Vancouver

Kirkwood JM, Mohr P, Hoeller C, Grob JJ, Del Vecchio M, Lord-Bessen J, et al. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115371

BibTeX
@article{Kirkwood2025,
  author = {Kirkwood, John M and Mohr, Peter and Hoeller, Christoph and Grob, Jean-Jacques and Del Vecchio, Michele and Lord-Bessen, Jennifer and Srinivasan, Swetha and Nassar, Ayman and Campigotto, Federico and Fairbanks, Hannah and Taylor, Fiona and Lawrance, Rachael and Long, Georgina V and Weber, Jeffrey},
  title = {Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115371}
}
Kostenlos starten →